About the Company
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma".Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod. Genome Protection Inc. subsequently received a $10.5 million (US) investment from Russian oligarch Roman Abramovich.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
4
Exchange
OTC MARKETS
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $STAB News
Statera BioPharma Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
DiaMedica Therapeutics Stock (NASDAQ:DMAC), Quotes and News Summary
Lisa Levin Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777.
TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized ...
SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is ...
Aytu BioPharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Vor Biopharma, Inc.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to ...
ARCA biopharma, Inc.
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on ...
POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know
Earnings Estimate Revisions for POINT Biopharma Global Inc. This company is expected to earn -$0.71 per share for the fiscal year ending December 2023, which represents a year-over-year change of ...
Statera BioPharma Inc Ordinary Shares STAB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Statera Biopharma, Inc. (STAB)
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune ...
Sunshine Biopharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Statera Biopharma, Inc. (STAB)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...